Roche: RoActemra beats Humira
Enlarge image


Roche: RoActemra beats Humira

08.06.2012 - Roche's rheumatoid arthritis treatment RoActemra reduces symptoms more effectively than Abbott Laboratories' Humira when given as a single treatment.

Basel – As the Swiss company reported, a Phase IV trial showed that after 24 weeks of treatment 65% of patients who received RoActemra (tocilizumab) experienced a 20% reduction in swollen and tender joints compared with 49% of those on Humira (adalimumab). „As there are a number of therapies approved for patients with rheumatoid arthritis, it is important for them and their healthcare provider to have the information they need to choose the best individual treatment option,“ said Hal Barron, Chief Medical Officer and Head, Global Product Development. While Roche strongly advocates for its RoActemra, Analysts seem to be less convinced: „Despite these strong efficacy results, it is difficult to assess whether these trial results can be successfully exploited to bring about a change in physicians' prescription habits,“ said Vontobel analyst Andrew Weiss.

„Among a treatment environment of nine different medicines, it is very difficult to make an individual treatment decision for the physician“, acknowledged Karsten Jung, Head of GPS Immunology at Roche, adding that the study aimed at giving comparative data to doctors to help them to decidea in favor of RoActemra when prescribing a treatment.

FDA and EMA have approved RoActemra for use in patients who are either intolerant to or have failed to respond to other medicines to treat inflammation. Roche earned CHF184m in the first quarter 2012 (+46%). Analysts expect peak sales of up to US$2b for the drug. Rheumatoid arthritis and related diseases are one of the most lucrative areas for pharma companies, generating more than US$20b in annual sales. Humira sales are expected to reach US$8.7bn in 2012, according to an EvaluatePharma report.


07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


18.09.2015 AstraZeneca has partnered up with the US Department of Health in order to accelerate the development of new antibiotics. The goal: to be prepared for multi-resistant bugs – and for bioterrorism.


17.09.2015 Another European biotech is coming with a hefty price tag for its US buyer. Amgen Inc. has acquired privatly held Dutch company Dezima Pharma B.V. for US$1.55bn (€1.37bn).


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • PHARMING (NL)0.31 EUR19.23%


  • THERAMETRICS (CH)0.04 CHF-33.33%
  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • THROMBOGENICS (B)4.13 EUR48.6%
  • OREXO (S)66.00 SEK36.9%
  • ZEALAND PHARMA (DK)156.00 DKK22.4%


  • THERAMETRICS (CH)0.04 CHF-33.3%
  • TIGENIX (B)0.88 EUR-27.9%


  • KARO BIO (S)43.60 SEK5282.7%
  • CHRONTECH PHARMA (S)0.35 SEK337.5%
  • GALAPAGOS (B)38.43 EUR225.7%


  • NEOVACS (F)0.70 EUR-77.8%
  • BIOTEST (D)19.15 EUR-74.6%
  • EVOCUTIS (UK)0.16 GBP-70.9%

No liability assumed, Date: 08.10.2015